search
Back to results

Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine

Primary Purpose

Acute Migraine

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Rimegepant
Placebo
Sponsored by
Biohaven Pharmaceuticals, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Migraine focused on measuring Migraine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Subject has at least 1 year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorder, 3rd Edition, Beta version including the following:

  1. Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age
  2. Migraine attacks, on average, lasting about 4-72 hours if untreated
  3. Not more than 8 attacks of moderate to severe intensity per month within the last 3 months
  4. Consistent migraine headaches of at least 2 migraine headache attacks of moderate or severe intensity in each of the 3 months prior to the Screening Visit and maintains this requirement during the Screening period
  5. Less than 15 days with headache (migraine or non-migraine) per month in each of the 3 months prior to the Screening Visit and maintains this requirement during the Screening Period.
  6. Subjects on prophylactic migraine medication are permitted to remain on therapy provided they have been on a stable dose for at least 3 months prior to screening visit and the dose is not expected to change during the course of the study.
  7. Subjects with contraindications for use of triptans may be included provided they meet all other study entry criteria.

Key Exclusion Criteria:

  1. Subject with a history of HIV disease
  2. Subject history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. subjects with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to screening
  3. Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however subjects can be included who have stable hypertension and/or diabetes for at least 3 months prior to being enrolled)
  4. Subject has a current diagnosis of major depression, other pain syndromes, psychiatric conditions (e.g., schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion might interfere with study assessments.
  5. Subject has a history of gastric, or small intestinal surgery (including Gastric Bypass, Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has disease that causes malabsorption
  6. The subject has a history of current or evidence of any significant and/ or unstable medical conditions (e.g., history of congenital heart disease or arrhythmia, known suspected infection, hepatitis B or C, or cancer) that, in the investigator's opinion, would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial.
  7. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months or subjects who have met DSM-V criteria for any significant substance use disorder within the past 12 months from the date of the screening visit.
  8. Subjects are excluded if they have previously participated in any study of rimegepant or other experimental CGRP-antagonist study, or have been prescribed CGRP-antibodies within the last 6 months
  9. Participation in any other investigational clinical trial while participating in this clinical trial

Sites / Locations

  • The First Affiliated Hospital of Bengbu Medical College
  • Anhui provincal Hospital
  • The Second Hospital of Anhui Medical University
  • Lu'An People's Hospital
  • The People's Hospital of Xuancheng City
  • Chinese PLA General Hospital
  • Peking University People's Hospital
  • Beijing Friendship Hospital,Capital Medical University
  • Chongqing Emergency Medical Center
  • The First Affiliated Hospital of Chongqing Medical University
  • Chonggang General Hospital
  • Chongqing Three Gorges Central Hospital
  • Fujian medical University Union Hospital
  • The 900th Hospital of Joint Logistics Support Force, PLA
  • Lanzhou University Second Hospital
  • Sun Yat-Sen Memorial Hospital of Zhongshan University
  • The First Affiliated Hospital of Hainan Medical College
  • Hainan General Hospital
  • Cangzhou Central Hospital
  • Henan University of Science and Technology First Affiliated Hospital
  • Henan Provincial People's Hospital
  • Zhengzhou People's Hospital
  • The First Affiliated Hospital of Zhengzhou University
  • Huanggang Central Hospital
  • Jingzhou Central Hospital
  • Taihe Hospital
  • Wuhan Fourth hospital
  • Renmin Hospital Of Wuhan University
  • Wuhan Third Hospital
  • Changsha Central Hospital
  • The Second Xiangya Hospital Of Central South University
  • The Third Xiangya Hospital Of Central South University
  • The Central Hospital of Shaoyang
  • The First People's Hospital of Yueyang
  • Zhuzhou Central Hospital
  • Zigong First People's Hospital
  • The first affiliated hospital of Baotou medical college of Inner Mongolia university of science and technology
  • Affiliated Hospital of Chifeng University
  • Inner Mongolia People's Hospital
  • The Second People's Hospital of Lianyungang
  • Nanjing Drum Tower Hospital
  • Zhongda Hospital Southeast University
  • The Second Affiliated Hospital of Nanjing Medical University
  • Nanjing Brain Hospital
  • The First Affiliated Hospital With Nanjing Medical University
  • Sir Run Run Hospital, Nanjing Medical University
  • Wuxi Integrated Traditional Chinese and Western Medicine Hospital
  • Wuxi people's Hospital
  • The Affiliated Hospital of Jiangsu University
  • 1st Hospital of Jilin University
  • The Second Hospital of Jilin University
  • General Hospital of Northern Theater Command
  • General Hospital of Ningxia Medical Hospital
  • The First People's Hospital of Yinchuan
  • Baoji Central Hospital
  • Xi'an Gaoxin Hospital Co., Ltd
  • The Second Affiliated Hospital of Xi'an Jiaotong University
  • Shaanxi Provincial People' Hospital
  • The First Affiliated Hospital of Xi'an Medical University
  • Yan'an University Xianyang Hospital Co., Ltd
  • Shandong Provincial Qianfoshan Hospital
  • Affiliated Hospital of Jining Medical University
  • Liaocheng People's Hospital
  • Qingdao Central Hospital
  • Zaozhuang Municipal Hospital
  • Shanghai East Hospital
  • Heping Hospital Affiliated to Changzhi Medical College
  • The Second Hospital of Shanxi Medical University
  • First Hospital of Shanxi Medical University
  • West China Hospital of Sichuan University
  • Nankai University, Tianjin Union Medical Center
  • Tianjin Huanhu Hospital
  • The Fifth Affiliated Hospital of Xinjiang Medical University
  • People's Hospital of Xinjiang Uygur Autonomous Region
  • The Second Affiliated Hospital of Xinjiang Medical University
  • The Second Affiliated hospital of Kunming Medical University
  • Ruian People's Hospital
  • Chuncheon Sacred Heart Hospital
  • Inje University Ilsan Paik Hospital
  • Dongtan Sacred Heart Hospital
  • Seoul National University Bundang Hospital
  • Chungnam National University Hospital
  • Nowon Eulji Medical Center
  • Seoul National University Hospital
  • Kangbuk Samsung Hospital
  • Severance Hospital
  • Kangdong Sacred Heart Hospital
  • Samsung Medical Center
  • Ewha Womans University Medical Center
  • Korea University Guro Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Rimegepant 75mg

Placebo

Arm Description

One 75mg oral disintegration tablet

Matching placebo

Outcomes

Primary Outcome Measures

To compare rimegepant to placebo on pain freedom.
Pain freedom will be measured by the number of subjects that report no pain. Pain freedom is measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe).
To compare rimegepant to placebo on freedom from Most Bothersome Symptom
Freedom from Most Bothersome Symptom will be measured using the number of subjects that report the absence of their MBS (nausea, phonophobia or photophobia) and will measured as (0=absent, 1=present).

Secondary Outcome Measures

To compare rimegepant to placebo on pain relief
Pain relief will be measured using the percentage of subjects with a pain intensity of none or mild.
To compare rimegepant to placebo on the ability to function normally at 2 hours post-dose as reported on the Functional Disability scale
The ability to function normally will be measured using the number of subjects that self-report as "normal" on the Functional Disability scale
To compare rimegepant to placebo on the Use of Rescue Medications
The use of rescue medications will be measured using the number of subjects that take rescue medication.
To compare rimegepant to placebo on sustained pain freedom
Pain freedom will be measured using the number of subjects that do not experience any headache pain.
To compare rimegepant to placebo on sustained pain freedom
Pain freedom will be measured using the number of subjects that do not experience any headache pain.
To compare rimegepant to placebo on pain freedom
Pain freedom will be measured using the number of subjects that report a pain level of moderate or severe just before taking study medication and then report a pain level of none at the timepoint of interest.
To compare rimegepant to placebo on freedom from Most Bothersome Symptom
Pain freedom will be measured using the number of subjects that report the absence of their Most Bothersome Symptom.
To compare rimegepant to placebo for the incidence of pain relapse
Pain relapse will be measured using the number of subjects that are pain free at 2 hours post-dose and then have a migraine of any pain severity (response of: 2 or 3 on the 4 point scale) within 48 hours.

Full Information

First Posted
September 27, 2020
Last Updated
December 15, 2022
Sponsor
Biohaven Pharmaceuticals, Inc.
Collaborators
BioShin Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT04574362
Brief Title
Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
Official Title
BHV3000-310: Phase 3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
October 22, 2020 (Actual)
Primary Completion Date
November 24, 2021 (Actual)
Study Completion Date
December 16, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Biohaven Pharmaceuticals, Inc.
Collaborators
BioShin Limited

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This trial is to determine whether BHV3000 (rimegepant) 75mg is safe and effictive as a treatment for acute migraine in Chinese and Korean patients
Detailed Description
Biohaven Pharmaceuticals, Inc. is the agent for BioShin Limited, the sponsor of the studies in China and Korea.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Migraine
Keywords
Migraine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1648 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Rimegepant 75mg
Arm Type
Active Comparator
Arm Description
One 75mg oral disintegration tablet
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Matching placebo
Intervention Type
Drug
Intervention Name(s)
Rimegepant
Intervention Description
One 75mg orally disintegrating tablet
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Matching placebo
Primary Outcome Measure Information:
Title
To compare rimegepant to placebo on pain freedom.
Description
Pain freedom will be measured by the number of subjects that report no pain. Pain freedom is measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe).
Time Frame
2 hours post-dose
Title
To compare rimegepant to placebo on freedom from Most Bothersome Symptom
Description
Freedom from Most Bothersome Symptom will be measured using the number of subjects that report the absence of their MBS (nausea, phonophobia or photophobia) and will measured as (0=absent, 1=present).
Time Frame
2 hours post-dose
Secondary Outcome Measure Information:
Title
To compare rimegepant to placebo on pain relief
Description
Pain relief will be measured using the percentage of subjects with a pain intensity of none or mild.
Time Frame
2 hours post-dose
Title
To compare rimegepant to placebo on the ability to function normally at 2 hours post-dose as reported on the Functional Disability scale
Description
The ability to function normally will be measured using the number of subjects that self-report as "normal" on the Functional Disability scale
Time Frame
2 hours post-dose
Title
To compare rimegepant to placebo on the Use of Rescue Medications
Description
The use of rescue medications will be measured using the number of subjects that take rescue medication.
Time Frame
24 hours post-dose
Title
To compare rimegepant to placebo on sustained pain freedom
Description
Pain freedom will be measured using the number of subjects that do not experience any headache pain.
Time Frame
2 to 24 hours post-dose
Title
To compare rimegepant to placebo on sustained pain freedom
Description
Pain freedom will be measured using the number of subjects that do not experience any headache pain.
Time Frame
2 to 48 hours post-dose
Title
To compare rimegepant to placebo on pain freedom
Description
Pain freedom will be measured using the number of subjects that report a pain level of moderate or severe just before taking study medication and then report a pain level of none at the timepoint of interest.
Time Frame
15, 30, 45, 60 and 90 minutes post-dose
Title
To compare rimegepant to placebo on freedom from Most Bothersome Symptom
Description
Pain freedom will be measured using the number of subjects that report the absence of their Most Bothersome Symptom.
Time Frame
15, 30, 45, 60 and 90 minutes post-dose
Title
To compare rimegepant to placebo for the incidence of pain relapse
Description
Pain relapse will be measured using the number of subjects that are pain free at 2 hours post-dose and then have a migraine of any pain severity (response of: 2 or 3 on the 4 point scale) within 48 hours.
Time Frame
2 to 48 hours post-dose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject has at least 1 year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorder, 3rd Edition, Beta version including the following: Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age Migraine attacks, on average, lasting about 4-72 hours if untreated Not more than 8 attacks of moderate to severe intensity per month within the last 3 months Consistent migraine headaches of at least 2 migraine headache attacks of moderate or severe intensity in each of the 3 months prior to the Screening Visit and maintains this requirement during the Screening period Less than 15 days with headache (migraine or non-migraine) per month in each of the 3 months prior to the Screening Visit and maintains this requirement during the Screening Period. Subjects on prophylactic migraine medication are permitted to remain on therapy provided they have been on a stable dose for at least 3 months prior to screening visit and the dose is not expected to change during the course of the study. Subjects with contraindications for use of triptans may be included provided they meet all other study entry criteria. Key Exclusion Criteria: Subject with a history of HIV disease Subject history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. subjects with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to screening Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however subjects can be included who have stable hypertension and/or diabetes for at least 3 months prior to being enrolled) Subject has a current diagnosis of major depression, other pain syndromes, psychiatric conditions (e.g., schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion might interfere with study assessments. Subject has a history of gastric, or small intestinal surgery (including Gastric Bypass, Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has disease that causes malabsorption The subject has a history of current or evidence of any significant and/ or unstable medical conditions (e.g., history of congenital heart disease or arrhythmia, known suspected infection, hepatitis B or C, or cancer) that, in the investigator's opinion, would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months or subjects who have met DSM-V criteria for any significant substance use disorder within the past 12 months from the date of the screening visit. Subjects are excluded if they have previously participated in any study of rimegepant or other experimental CGRP-antagonist study, or have been prescribed CGRP-antibodies within the last 6 months Participation in any other investigational clinical trial while participating in this clinical trial
Facility Information:
Facility Name
The First Affiliated Hospital of Bengbu Medical College
City
Bengbu
State/Province
Anhui
ZIP/Postal Code
233030
Country
China
Facility Name
Anhui provincal Hospital
City
Hefei
State/Province
Anhui
ZIP/Postal Code
230001
Country
China
Facility Name
The Second Hospital of Anhui Medical University
City
Hefei
State/Province
Anhui
ZIP/Postal Code
230601
Country
China
Facility Name
Lu'An People's Hospital
City
Lu'an
State/Province
Anhui
ZIP/Postal Code
237011
Country
China
Facility Name
The People's Hospital of Xuancheng City
City
Xuancheng
State/Province
Anhui
ZIP/Postal Code
242299
Country
China
Facility Name
Chinese PLA General Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100039
Country
China
Facility Name
Peking University People's Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100044
Country
China
Facility Name
Beijing Friendship Hospital,Capital Medical University
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100050
Country
China
Facility Name
Chongqing Emergency Medical Center
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400014
Country
China
Facility Name
The First Affiliated Hospital of Chongqing Medical University
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400042
Country
China
Facility Name
Chonggang General Hospital
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400080
Country
China
Facility Name
Chongqing Three Gorges Central Hospital
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
404199
Country
China
Facility Name
Fujian medical University Union Hospital
City
Fuzhou
State/Province
Fujian
ZIP/Postal Code
350001
Country
China
Facility Name
The 900th Hospital of Joint Logistics Support Force, PLA
City
Fuzhou
State/Province
Fujian
ZIP/Postal Code
350025
Country
China
Facility Name
Lanzhou University Second Hospital
City
Lanzhou
State/Province
Gansu
ZIP/Postal Code
730030
Country
China
Facility Name
Sun Yat-Sen Memorial Hospital of Zhongshan University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510120
Country
China
Facility Name
The First Affiliated Hospital of Hainan Medical College
City
Haikou
State/Province
Hainan
ZIP/Postal Code
570102
Country
China
Facility Name
Hainan General Hospital
City
Haikou
State/Province
Hainan
ZIP/Postal Code
570311
Country
China
Facility Name
Cangzhou Central Hospital
City
Cangzhou
State/Province
Hebei
ZIP/Postal Code
061017
Country
China
Facility Name
Henan University of Science and Technology First Affiliated Hospital
City
Luoyang
State/Province
Henan
ZIP/Postal Code
471003
Country
China
Facility Name
Henan Provincial People's Hospital
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450003
Country
China
Facility Name
Zhengzhou People's Hospital
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450014
Country
China
Facility Name
The First Affiliated Hospital of Zhengzhou University
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450052
Country
China
Facility Name
Huanggang Central Hospital
City
Huanggang
State/Province
Hubei
ZIP/Postal Code
438099
Country
China
Facility Name
Jingzhou Central Hospital
City
Jingzhou
State/Province
Hubei
ZIP/Postal Code
434020
Country
China
Facility Name
Taihe Hospital
City
Shiyan
State/Province
Hubei
ZIP/Postal Code
442000
Country
China
Facility Name
Wuhan Fourth hospital
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430034
Country
China
Facility Name
Renmin Hospital Of Wuhan University
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430060
Country
China
Facility Name
Wuhan Third Hospital
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430073
Country
China
Facility Name
Changsha Central Hospital
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410004
Country
China
Facility Name
The Second Xiangya Hospital Of Central South University
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410011
Country
China
Facility Name
The Third Xiangya Hospital Of Central South University
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410013
Country
China
Facility Name
The Central Hospital of Shaoyang
City
Shaoyang
State/Province
Hunan
ZIP/Postal Code
422099
Country
China
Facility Name
The First People's Hospital of Yueyang
City
Yueyang
State/Province
Hunan
ZIP/Postal Code
414000
Country
China
Facility Name
Zhuzhou Central Hospital
City
Zhuzhou
State/Province
Hunan
ZIP/Postal Code
412007
Country
China
Facility Name
Zigong First People's Hospital
City
Sichuan
State/Province
Igong
ZIP/Postal Code
643000
Country
China
Facility Name
The first affiliated hospital of Baotou medical college of Inner Mongolia university of science and technology
City
Baotou
State/Province
Inner Mongolia
ZIP/Postal Code
014010
Country
China
Facility Name
Affiliated Hospital of Chifeng University
City
Chifeng
State/Province
Inner Mongolia
ZIP/Postal Code
024050
Country
China
Facility Name
Inner Mongolia People's Hospital
City
Hohhot
State/Province
Inner Mongolia
ZIP/Postal Code
010017
Country
China
Facility Name
The Second People's Hospital of Lianyungang
City
Lianyungang
State/Province
Jiangsu
ZIP/Postal Code
222023
Country
China
Facility Name
Nanjing Drum Tower Hospital
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210008
Country
China
Facility Name
Zhongda Hospital Southeast University
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210009
Country
China
Facility Name
The Second Affiliated Hospital of Nanjing Medical University
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210028
Country
China
Facility Name
Nanjing Brain Hospital
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210029
Country
China
Facility Name
The First Affiliated Hospital With Nanjing Medical University
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210029
Country
China
Facility Name
Sir Run Run Hospital, Nanjing Medical University
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
211112
Country
China
Facility Name
Wuxi Integrated Traditional Chinese and Western Medicine Hospital
City
Wuxi
State/Province
Jiangsu
ZIP/Postal Code
214000
Country
China
Facility Name
Wuxi people's Hospital
City
Wuxi
State/Province
Jiangsu
ZIP/Postal Code
214043
Country
China
Facility Name
The Affiliated Hospital of Jiangsu University
City
Zhenjiang
State/Province
Jiangsu
ZIP/Postal Code
212001
Country
China
Facility Name
1st Hospital of Jilin University
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130021
Country
China
Facility Name
The Second Hospital of Jilin University
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130041
Country
China
Facility Name
General Hospital of Northern Theater Command
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110015
Country
China
Facility Name
General Hospital of Ningxia Medical Hospital
City
Yinchuan
State/Province
Ning Xia
ZIP/Postal Code
750003
Country
China
Facility Name
The First People's Hospital of Yinchuan
City
Yinchuan
State/Province
Ningxia
ZIP/Postal Code
750001
Country
China
Facility Name
Baoji Central Hospital
City
Baoji
State/Province
Shaanxi
ZIP/Postal Code
721008
Country
China
Facility Name
Xi'an Gaoxin Hospital Co., Ltd
City
Xi'an
State/Province
Shaanxi
ZIP/Postal Code
710000
Country
China
Facility Name
The Second Affiliated Hospital of Xi'an Jiaotong University
City
Xi'an
State/Province
Shaanxi
ZIP/Postal Code
710004
Country
China
Facility Name
Shaanxi Provincial People' Hospital
City
Xi'an
State/Province
Shaanxi
ZIP/Postal Code
710068
Country
China
Facility Name
The First Affiliated Hospital of Xi'an Medical University
City
Xi'an
State/Province
Shaanxi
ZIP/Postal Code
710077
Country
China
Facility Name
Yan'an University Xianyang Hospital Co., Ltd
City
Xianyang
State/Province
Shaanxi
ZIP/Postal Code
712000
Country
China
Facility Name
Shandong Provincial Qianfoshan Hospital
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250013
Country
China
Facility Name
Affiliated Hospital of Jining Medical University
City
Jining
State/Province
Shandong
ZIP/Postal Code
272029
Country
China
Facility Name
Liaocheng People's Hospital
City
Liaocheng
State/Province
Shandong
ZIP/Postal Code
252004
Country
China
Facility Name
Qingdao Central Hospital
City
Qingdao
State/Province
Shandong
ZIP/Postal Code
266042
Country
China
Facility Name
Zaozhuang Municipal Hospital
City
Zaozhuang
State/Province
Shandong
ZIP/Postal Code
277102
Country
China
Facility Name
Shanghai East Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200120
Country
China
Facility Name
Heping Hospital Affiliated to Changzhi Medical College
City
Changzhi
State/Province
Shanxi
ZIP/Postal Code
046099
Country
China
Facility Name
The Second Hospital of Shanxi Medical University
City
Taiyuan
State/Province
Shanxi
ZIP/Postal Code
030000
Country
China
Facility Name
First Hospital of Shanxi Medical University
City
Taiyuan
State/Province
Shanxi
ZIP/Postal Code
030001
Country
China
Facility Name
West China Hospital of Sichuan University
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610041
Country
China
Facility Name
Nankai University, Tianjin Union Medical Center
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300121
Country
China
Facility Name
Tianjin Huanhu Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300222
Country
China
Facility Name
The Fifth Affiliated Hospital of Xinjiang Medical University
City
Xinjiang
State/Province
Uramqi
ZIP/Postal Code
830011
Country
China
Facility Name
People's Hospital of Xinjiang Uygur Autonomous Region
City
Xinjiang
State/Province
Wulumuqi
ZIP/Postal Code
830001
Country
China
Facility Name
The Second Affiliated Hospital of Xinjiang Medical University
City
Xinjiang
State/Province
Wulumuqi
ZIP/Postal Code
830018
Country
China
Facility Name
The Second Affiliated hospital of Kunming Medical University
City
Kunming
State/Province
Yunnan
ZIP/Postal Code
650101
Country
China
Facility Name
Ruian People's Hospital
City
Rui'an
State/Province
Zhejiang
ZIP/Postal Code
325299
Country
China
Facility Name
Chuncheon Sacred Heart Hospital
City
Chuncheon
State/Province
Gangwon
ZIP/Postal Code
24253
Country
Korea, Republic of
Facility Name
Inje University Ilsan Paik Hospital
City
Goyang-si
State/Province
Gyeonggi-do
ZIP/Postal Code
10380
Country
Korea, Republic of
Facility Name
Dongtan Sacred Heart Hospital
City
Hwaseong-si
State/Province
Gyeonggi-do
ZIP/Postal Code
18450
Country
Korea, Republic of
Facility Name
Seoul National University Bundang Hospital
City
Seongnam-si
State/Province
Gyeonggi-do
ZIP/Postal Code
13620
Country
Korea, Republic of
Facility Name
Chungnam National University Hospital
City
Daejeon
ZIP/Postal Code
35015
Country
Korea, Republic of
Facility Name
Nowon Eulji Medical Center
City
Seoul
ZIP/Postal Code
01830
Country
Korea, Republic of
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Facility Name
Kangbuk Samsung Hospital
City
Seoul
ZIP/Postal Code
03181
Country
Korea, Republic of
Facility Name
Severance Hospital
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Facility Name
Kangdong Sacred Heart Hospital
City
Seoul
ZIP/Postal Code
05355
Country
Korea, Republic of
Facility Name
Samsung Medical Center
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Facility Name
Ewha Womans University Medical Center
City
Seoul
ZIP/Postal Code
07804
Country
Korea, Republic of
Facility Name
Korea University Guro Hospital
City
Seoul
ZIP/Postal Code
08308
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine

We'll reach out to this number within 24 hrs